Mineralys Therapeutics Reports $43.3 Million Net Loss in Q2 2025

Mineralys Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $43.3 million, compared to a loss of $41.0 million in the same period of 2024. For the first half of 2025, the company recorded a net loss of $85.5 million, up from $72.5 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $76.2 million from $70.0 million, primarily due to increased compensation costs and clinical trial expenses. General and administrative expenses also increased to $15.0 million from $10.5 million, reflecting higher personnel costs and professional fees.

Mineralys' total operating expenses for the second quarter of 2025 were $46.7 million, slightly higher than the $45.2 million reported in the same quarter of 2024. The company’s cash and cash equivalents decreased to $101.8 million as of June 30, 2025, down from $114.1 million at the end of 2024. However, total current assets increased significantly to $335.3 million, driven by a rise in investments, which reached $223.1 million compared to $84.1 million at the end of the previous year.

Strategically, Mineralys has made significant progress in its clinical development of lorundrostat, an aldosterone synthase inhibitor aimed at treating hypertension and related conditions. The company successfully completed pivotal trials, including the Launch-HTN and Advance-HTN studies, which demonstrated statistically significant efficacy in reducing blood pressure. These results are expected to support a New Drug Application (NDA) meeting with the FDA planned for the fourth quarter of 2025. Additionally, the company is conducting a Phase 2 trial for lorundrostat in patients with obstructive sleep apnea, further expanding its clinical program.

In terms of financing, Mineralys raised approximately $188.7 million from a public offering in March 2025 and an additional $9.5 million from an At-the-Market (ATM) equity offering. The company has raised a total of approximately $717.4 million since its inception, primarily through equity offerings. As of June 30, 2025, Mineralys reported an accumulated deficit of $388.0 million, indicating the ongoing financial challenges typical for clinical-stage biopharmaceutical companies.

Looking ahead, Mineralys anticipates continued operating losses as it advances its clinical trials and seeks regulatory approval for lorundrostat. The company believes its current cash and investments will be sufficient to fund operations for at least the next twelve months. However, it acknowledges the need for additional funding to support its research and development activities and operational growth, which may come from future equity offerings or strategic collaborations.